DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
Since First Approved and Launched Bispecific Antibody In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 121% CAGR Till 2020
This report predicts that in the next few successful years of clinical research studies associated with the therapy, it will lead to completely revolutionize the entire cancer treatment regimen and the overall future direction of cancer therapeutics. By growing at an accelerated speed in small period of time, the therapy market has also remained successful in getting represented as one of the most exciting approach in the entire biotech space and sector. Increase in the volume of recent publications, articles and research papers with respect to the therapy applications by manipulating it at molecular level by the available tools are also estimated to expand the market parameters. In addition, the unprecedented market drivers associated with the therapy are also believed to be digging deep to increase the performance rate of the therapy. To conclude, it can be stated that the overall therapy market achievements are commitment to cause a total advancement in the global cancer therapeutics market by acting broad spectrally.
Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights:
- Global Bispecific Antibody Market Opportunity: > US$ 18 Billion
- Global Bispecific Antibody Market Growth Rate: 121% CAGR (2016-2020)
- Global Bispecific Antibody Sales In 2020: >55%
- Bispecific Antibodies In Clinical Trials: More Than 400 Antibodies
- Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
- Approved Bispecific Antibodies Dosage, Patent, Price, Yearly Sales, Quarterly Sales, Global and Regional Sales Insight
The unique achievements gathered through monoclonal antibody market led to the identification of novel wave of antibody market classified as Bispecific cancer antibody market. In a very imperative and innovative way, bispecific cancer antibody market applications have prompted the oncology researchers to multiply the healthcare benefits received by the patients suffering from different types of cancers. The whole procedure followed by the drugs available under the market involves targeting two specific molecules present on the surface of cancer antigens. The same has been verified in several different pre-clinical and clinical settings, thus anticipating the therapy market to deliver promising healthcare outcomes to the patients who have developed resistance to other available therapies.
Currently 2 Bispecific Antibodies Blincyto And Hemlibra Are Commercially Available In Market, Hemlibra Accounts For More Than 85% Of Global Bispecific Antibody Market
In the past few years, global bispecific cancer antibody market has cleared its clinical evaluation for different types of cancers which involves: cancer at early stage, last stage and solid cancers. More precisely, the therapy at an international level is getting leveraged due to its uniqueness and imperative approach of targeting molecules which are highly differentiated in all sub-types of cancers. Despite of introducing monoclonal antibody therapy in the cancer therapeutics several decades ago, researchers got to acknowledge the applications of adding the capability of an antibody to act on two targets few years ago. It is predicted that advancement in pharmaceutical market technology, thanks to science and medical progress, the therapy is leading the entire cancer therapeutics market towards a novel era of progress and scientific achievements.
Key Topics Covered:
1. Introduction to Bispecific Monoclonal Antibody
2. Advantage of Bispecific Antibodies Over Monospecific Monoclonal Antibodies
3. Bispecific Antibodies - Development Process & Mechanism of Action
3.1 Development of Bispecific Antibodies Similar to IgG
3.2 Development of Small Bispecific Antibodies
3.3 General Mechanism of Bispecific Antibodies
4. Approved Bispecific Antibodies Mechanism of Action
4.1 Hemlibra
4.2 Blincyto
5. Application of Bispecific Antibodies in Cancer
5.1 Cancer Diagnosis
5.2 Cancer Targeting By Blocking Signaling Pathways
5.3 Targeting Tumor Angiogenesis for Cancer Treatment
6. Miscellaneous Application of Bispecific Antibodies
6.1 Diagnosis of Microbial Infectious Diseases
6.2 Specific Delivery of Effector Compounds to Targets
6.3 Bispecific Antibodies as Genetic Antibody Therapy
7. Global & Regional Bispecific Antibody Market Outlook
7.1 Yearly & Quarterly Indicators
7.2 Approved Bispecific Antibodies Reimbursement Policy
7.3 Blincyto Reimbursement Policy
7.4 Hemlibra Reimbursement Policy
8. Blincyto: First Approved Bispecific Antibody 2015
8.1 Dosage & Price Analysis
8.2 Global & Regional Sales Analysis
9. Hemlibra: Second Approved Bispecific Antibody 2018
9.1 Dosage & Price Analysis
9.2 Global & Regional Sales Analysis
10. Global Bispecific Antibodies Clinical Pipeline Overview
10.1 By Phase
10.2 By Country/Region
10.3 By Company
10.4 By Indication
10.5 Orphan Designated Bispecific Antibodies
10.6 Patient Segment
11. Ongoing Bispecific Antibodies Clinical Trials By Company, Country, Indication & Phase
12. Marketed Bispecific Antibodies Clinical Insight
12.1 Blinatumomab - Amgen
12.2 Emicizumab - Chugai Pharmaceutical
13. Global Bispecific Antibody Market Dynamics
13.1 Favorable Market Parameters
13.2 Commercialization Challenges
14. Global Bispecific Antibody Market Future Prospects
15. Competitive Landscape
15.1 Ablynx
15.2 Adimab
15.3 Affimed Therapeutics
15.4 Amgen
15.5 AstraZeneca (MedImmune)
15.6 Chugai Pharmaceutical
15.7 Eli Lilly
15.8 EMD Serono
15.9 Emergent BioSolutions
15.10 Genentech
15.11 Genmab
15.12 Immunomedics
15.13 Jounce Therapeutics
15.14 MacroGenics
15.15 Merus
15.16 Neovii Biotech
15.17 NovImmune SA
15.18 OncoMed Pharmaceuticals
15.19 Pieris
15.20 Regeneron Pharmaceuticals
15.21 Roche
15.22 Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/6fabny
